HKSE · 9969.HK
InnoCare Pharma Limited
HK$11.65-HK$0.02 (-0.17%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 28.02% below the high.
Loading market information…
HKSE · 1167.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 05:01 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Jacobio Pharmaceuticals Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 49.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Jacobio Pharmaceuticals Group Co., Ltd.’s next earnings report is currently expected on Mar 24, 2027, with estimated earnings per share of HK$0.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jacobio Pharmaceuticals Group Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$0.00 |
| Q4 2023 | Mar 28, 2024 | -HK$0.28+7.41% vs estimate | HK$25.51M+17.9% vs estimate |
|---|
| Q2 2023 | Aug 30, 2023 | -HK$0.24+24.14% vs estimate | HK$43.59M+34.45% vs estimate |
|---|
| Q4 2022 | Mar 22, 2023 | -HK$0.36-14.29% vs estimate | HK$46.48M-56.92% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$11.65-HK$0.02 (-0.17%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 28.02% below the high.
HK$28.30+HK$0.08 (+0.28%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.19% below the high.
HK$24.22-HK$0.74 (-2.96%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.22% below the high.
HK$6.41+HK$0.07 (+1.03%)
Abbisko Cayman Limited’s quoted price sits in the lower half of its reported 52-week range, 57.42% below the high.
HK$8.85+HK$0.19 (+2.2%)
TransThera Sciences (Nanjing). Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.4% below the high.
HK$9.23-HK$0.37 (-3.8%)
Impact Therap-b’s quoted price sits in the lower half of its reported 52-week range, 80.76% below the high.
HK$5.86+HK$0.23 (+3.99%)
Laekna, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.73% below the high.
HK$2.87+HK$0.05 (+1.59%)
Antengene Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 54.3% below the high.
